Vera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vera Therapeutics (VERA).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

12Buy

2Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$66Upside to Avg. PT+113.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Leerink Partners	Will Soghikian	Initiate	Market Perform	$34
Sep 8, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$76→$83
Aug 17, 2026	Wedbush	Laura Chico	Maintained	Neutral	$34
Aug 12, 2026	HC Wainwright & Co.	Arthur He	PT Cut	Buy	$125→$90
Aug 11, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$43→$34
Jul 8, 2026	TD Cowen	Ritu Baral	PT Raise	Buy	$73→$78
Jul 8, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$56→$76
Jul 8, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$35→$43
Jul 8, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$110→$125
Jul 7, 2026	B of A Securities	Dina Ramadane	PT Raise	Buy	$65→$70
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$95→$91
Mar 11, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	$88
Mar 2, 2026	HC Wainwright & Co.	Arthur He	PT Raise	Buy	$90→$110
Dec 19, 2025	B of A Securities	Dina Ramadane	PT Raise	Buy	$48→$66
Dec 19, 2025	Goldman Sachs	Paul Choi	PT Raise	Buy	$55→$95
Dec 19, 2025	JP Morgan	Anupam Rama	PT Cut	Overweight	$99→$96
Dec 11, 2025	Wedbush	Laura Chico	PT Raise	Neutral	$23→$33
Dec 8, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$75→$97
Dec 5, 2025	TD Cowen	Ritu Baral	PT Raise	Buy	$60→$73
Dec 3, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$52→$99

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

Leerink Partners analyst Will Soghikian initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Market Perform rating and announces Price Target of $34.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.

Benzinga Newsdesk

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

Wedbush analyst Laura Chico reiterates Vera Therapeutics (NASDAQ:VERA) with a Neutral and maintains $34 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

HC Wainwright & Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and lowers the price target from $125 to $90.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

TD Cowen analyst Ritu Baral maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $73 to $78.

Benzinga Newsdesk

Vera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Vera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

People Also Watch

People Also Watch

Vera Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Vera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PROJP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PROWedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PROHC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PROWedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PROTD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

People Also Watch

People Also Watch

PRO
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34

PRO
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83

PRO
Wedbush Reiterates Neutral on Vera Therapeutics, Maintains $34 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90

PRO
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34

PRO
TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78